Bausch + Lomb announces acquisition of the Blink OTC line of eye drops
The product line will be acquired for $106.5 million, and will add another half dozen products to the company’s over-the-counter eye care product portfolio.
(Adobe Stock / killykoon)
Bausch + Lomb has announced the acquisition of the Blink over-the-counter (OTC) line of eye drops from Johnson & Johnson Vision for the agreed upon price of $106.5 million. This most recent purchase adds to the company’s commitment to continue increasing consumer convenience with OTC eye care products.1
A variety of a half dozen products of eye drops and contact lens rewetting drops make up the Blink portfolio. These products include: Blink Tears Lubricating Eye Drops, Blink Tears Preservative Free Lubricating Eye Drops, Blink GelTears Lubricating Eye Drops, Blink Triple Care Lubricating Eye Drops, Blink Contacts Lubricating Eye Drops, and Blink-N-Clean Lens Drops.
“There’s a growing need for relieving the symptoms of dry eyes and dry contact lenses, and OTC products are often the first option consumers choose,” said John Ferris, executive vice president, Consumer, Bausch + Lomb. “The addition of Blink expands our robust portfolio of OTC eye care brands, enabling us to provide more choices for consumers and eye care professionals.”
In a Gallup Study from 2022, 57% of American adults reported experiencing dry eye symptoms, and nearly half (48%) of those individuals find relief from OTC lubricant drops.2 As this number continues to rise, especially with the use of digital devices, it is believed that contact lens discomfort and dryness affects a third of the 45 million contact lens wearers in the United States.3,4,5
More information about Blink eye drops can be found at www.justblink.com.
